A three-phase study designed to test the efficacy, tolerability and safety of the combination of Ziprasidone with the selective serotonin reuptake inhibitor (SSRI) Escitalopram for patients with Major Depressive Disorder (MDD) that do not sufficiently respond to treatment with Escitalopram
The current research study is looking for participants between the ages of 18-65, who are depressed and are not currently taking any medication. If eligible, participants will receive the FDA approved antidepressant medication Escitalopram (Lexapro) for at least 10 weeks. At the end of 10 weeks, subjects who have improved on the medication will be offered 3 months of follow up care at no cost. For those subjects who have NOT improved on the medication, they may be eligible to continue on Lexapro and receive, in addition, either Ziprasidone or placebo. Placebo is sometimes called a sugar pill, and it looks like a study drug but it doesn’t contain any active medication. At the end of the study, all participants will be offered 3 months of follow up care at no cost.
For more information about this and other depression studies, please call 1-877-55-BLUES or contact Vicki directly at 617-724-9458 or vameral@partners.org
We initiate new studies regularly, so please contact us for additional information.